Diabetic distal symmetric sensorimotor polyneuropathy (DSPN) is a common complication of diabetes with devastating consequences. Hyperglycaemia is the major aetiological factor, while emerging data demonstrate that cardiometabolic risk factors also contribute to its development. Diagnosis of DSPN involves interview of medical and neurological history, foot inspection, and sensory and motor function examination with specific tests such as temperature and pinprick perception for small nerve fibers, and vibration and light touch assessments for large nerve fibers. Management includes optimised glycaemic control, treatment of cardiovascular risk factors, and symptomatic treatment aiming at improving life quality. This article provides an overview on epidemiology, risk factors, classification, diagnosis and current treatment of DSPN.
GalerBSGianasAJensenMP. Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47(2):123-128.
2.
Pop-BusuiRBoultonAJFeldmanEL, et al.Diabetic neuropathy: A position statement by the American diabetes association. Diabetes Care. 2017;40(1):136-154.
3.
HicksCWWangDMatsushitaKWindhamBGSelvinE. Peripheral neuropathy and all-cause and cardiovascular mortality in U.S. adults: A prospective cohort study. Ann Intern Med. 2021;174(2):167-174.
4.
ArmstrongDGTanTWBoultonAJMBusSA. Diabetic foot ulcers: A review. JAMA. 2023;330(1):62-75.
5.
TesfayeSBrillSEerdekensM, et al.Diagnosis, management and impact of painful diabetic peripheral neuropathy: A patient survey in four European countries. J Diabetes Complications. 2023;37(4):108417.
6.
TentolourisAEleftheriadouITentolourisNPapanasN. Highlights from the 82(nd) ADA scientific sessions and the 58(th) EASD meeting on diabetic neuropathy. Int J Low Extrem Wounds. Published online May 22, 2023. doi:https://doi.org/10.1177/15347346231177569
7.
ZieglerDPapanasNVinikAIShawJE. Epidemiology of polyneuropathy in diabetes and prediabetes. Handb Clin Neurol. 2014;126:3-22.
8.
IqbalZAzmiSYadavR, et al.Diabetic peripheral neuropathy: Epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40(6):828-849.
9.
AbbottCAMalikRAvan RossERKulkarniJBoultonAJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UKDiabetes Care. 2011;34(10):2220-2224.
10.
YoungMJBoultonAJMacLeodAFWilliamsDRSonksenPH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993;36(2):150-154.
11.
Ismail-BeigiFCravenTBanerjiMA, et al.Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet. 2010;376(9739):419-430.
12.
DyckPJDaviesJLWilsonDMServiceFJMelton LJ 3rdO'BrienPC. Risk factors for severity of diabetic polyneuropathy: Intensive longitudinal assessment of the Rochester diabetic neuropathy study cohort. Diabetes Care. 1999;22(9):1479-1486.
13.
TesfayeSChaturvediNEatonSE, et al.Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341-350.
14.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
15.
AndersenSTWitteDRDalsgaardEM, et al.Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITION-Denmark. Diabetes Care. 2018;41(5):1068-1075.
16.
BansalVKalitaJMisraUK. Diabetic neuropathy. Postgrad Med J. 2006;82(964):95-100.
17.
DyckPJKratzKMKarnesJL, et al.The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort. The Rochester Diabetic Neuropathy Study. 1993;43(4):817.
18.
Pop-BusuiRHermanWHFeldmanEL, et al.DCCT And EDIC studies in type 1 diabetes: Lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. 2010;10(4):276-282.
19.
AzadNEmanueleNVAbrairaC, et al.The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications. 1999;13(5-6):307-313.
20.
GaedePVedelPLarsenNJensenGVParvingHHPedersenO. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393. doi:https://doi.org/10.1056/NEJMoa021778
21.
YoungMJBreddyJLVevesABoultonAJ. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care. 1994;17(6):557-560.
22.
HuYMZhaoLHZhangXL, et al.Association of glycaemic variability evaluated by continuous glucose monitoring with diabetic peripheral neuropathy in type 2 diabetic patients. Endocrine. 2018;60(2):292-300.
23.
PonirakisGPetropoulosINAlamU, et al.Hypertension contributes to neuropathy in patients with type 1 diabetes. Am J Hypertens. 2019;32(8):796-803.
24.
ChengYCaoWZhangJ, et al.Determinants of diabetic peripheral neuropathy and their clinical significance: A retrospective cohort study. Front Endocrinol (Lausanne). 2022;13:934020. Published 2022 Jul 26.
25.
van der VeldeJKosterAStrotmeyerES, et al.Cardiometabolic risk factors as determinants of peripheral nerve function: The Maastricht study. Diabetologia. 2020;63(8):1648-1658.
26.
GregoryJAJolivaltCGGoorJMizisinAPCalcuttNA. Hypertension-induced peripheral neuropathy and the combined effects of hypertension and diabetes on nerve structure and function in rats. Acta Neuropathol. 2012;124(4):561-573.
27.
OzakiKMatsuuraT. Superimposition of hypertension on diabetic peripheral neuropathy affects small unmyelinated sensory nerves in the skin and myelinated tibial and sural nerves in rats with alloxan-induced type 1 diabetes. J Toxicol Pathol. 2020;33(3):161-169.
28.
ElliottJTesfayeSChaturvediN, et al.Large-fiber dysfunction in diabetic peripheral neuropathy is predicted by cardiovascular risk factors. Diabetes Care. 2009;32(10):1896-1900.
29.
CaiZYangYZhangJ. A systematic review and meta-analysis of the serum lipid profile in prediction of diabetic neuropathy. Sci Rep. 2021;11(1):499.
30.
AfshinniaFReynoldsELRajendiranTM, et al.Serum lipidomic determinants of human diabetic neuropathy in type 2 diabetes. Ann Clin Transl Neurol. 2022;9(9):1392-1404.
31.
SmithAGSingletonJR. Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. J Diabetes Complications. 2013;27(5):436-442.
32.
RajamaniKColmanPGLiLP, et al.Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): A prespecified analysis of a randomised controlled trial. Lancet. 2009;373(9677):1780-1788.
33.
DavisTMYeapBBDavisWABruceDG. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: The fremantle diabetes study. Diabetologia. 2008;51(4):562-566.
34.
SchlesingerSHerderCKannenbergJM, et al.General and abdominal obesity and incident distal sensorimotor polyneuropathy: Insights into inflammatory biomarkers as potential mediators in the KORA F4/FF4 cohort. Diabetes Care. 2019;42(2):240-247.
35.
ZhouRLiFChenGFuQGuSWuX. Associations between general and abdominal obesity and incident diabetic neuropathy in participants with type 2 diabetes mellitus. J Diabetes. 2021;13(1):33-42.
36.
AdamSAzmiSHoJH, et al.Improvements in diabetic neuropathy and nephropathy after bariatric surgery: A prospective cohort study. Obes Surg. 2021;31(2):554-563.
37.
YlitaloKRSowersMHeeringaS. Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity: National health and nutrition examination survey 2001-2004. Diabetes Care. 2011;34(7):1642-1647.
38.
ChoYNLeeKOJeongJ, et al.The role of insulin resistance in diabetic neuropathy in Koreans with type 2 diabetes mellitus: A 6-year follow-up study. Yonsei Med J. 2014;55(3):700-708.
39.
CallaghanBCXiaRBanerjeeM, et al.Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status. Diabetes Care. 2016;39(5):801-807.
40.
LeeCCPerkinsBAKayaniyilS, et al.Peripheral neuropathy and nerve dysfunction in individuals at high risk for type 2 diabetes: The PROMISE cohort. Diabetes Care. 2015;38(5):793-800.
41.
PartanenJNiskanenLLehtinenJMervaalaESiitonenOUusitupaM. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(2):89-94.
42.
YokoyamaHTsujiTHayashiSKabataDShintaniA. Factors associated with diabetic polyneuropathy-related sensory symptoms and signs in patients with polyneuropathy: A cross-sectional Japanese study (JDDM 52) using a non-linear model. J Diabetes Investig. 2020;11(2):450-457.
43.
Dinh LeTPhi Thi NguyenNThanh Thi TranH, et al.Diabetic peripheral neuropathy associated with cardiovascular risk factors and glucagon-like peptide-1 concentrations among newly diagnosed patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2022;15:35-44.
44.
SzwarcbardNVillaniMEarnestA, et al.The association of smoking status with glycemic control, metabolic profile and diabetic complications- results of the Australian national diabetes audit (ANDA). J Diabetes Complications. 2020;34(9):107626.
45.
SloanGPanQGaoLGuoLTesfayeS. Clinical features of diabetes neuropathies. In: TesfayeSGibbonsCMalikRVevesA, eds. Diabetic neuropathy: advances in pathophysiology and clinical management. Springer International Publishing; 2023:37-49.
46.
TsapasALiakosAPaschosP, et al.A simple plaster for screening for diabetic neuropathy: A diagnostic test accuracy systematic review and meta-analysis. Metabolism. 2014;63(4):584-592.
47.
McIllhattonALantingSLambkinDLeighLCaseySChuterV. Reliability of recommended non-invasive chairside screening tests for diabetes-related peripheral neuropathy: a systematic review with meta-analyses. BMJ Open Diabetes Res Care. 2021;9(2).
48.
FeldmanELStevensMJThomasPKBrownMBCanalNGreeneDA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281-1289.
49.
ZieglerDHanefeldMRuhnauKJ, et al.Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN study). Diabetologia. 1995;38(12):1425-1433.
50.
SelvarajahDKarDKhuntiK, et al.Diabetic peripheral neuropathy: Advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol. 2019;7(12):938-948.
51.
BönhofGJHerderCStromAPapanasNRodenMZieglerD. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev. 2019;40(1):153-192.
52.
TerkelsenAJKarlssonPLauriaGFreemanRFinnerupNBJensenTS. The diagnostic challenge of small fibre neuropathy: Clinical presentations, evaluations, and causes. Lancet Neurol. 2017;16(11):934-944.
53.
GwathmeyKGPearsonKT. Diagnosis and management of sensory polyneuropathy. Br Med J. 2019;365:l1108.
54.
DySMBennettWLSharmaR, et al.Preventing complications and treating symptoms of diabetic peripheral neuropathy. Agency for healthcare research and quality (US); March 2017.
55.
FinnerupNBAttalNHaroutounianS, et al.Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-173.
56.
ArdeleanuVTomaAPafiliK, et al.Current pharmacological treatment of painful diabetic neuropathy: a narrative review. Medicina (Kaunas). 2020;56(1).
57.
ElSayedNAAleppoGArodaVR, et al.12. Retinopathy, neuropathy, and foot care: Standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S203-SS15.
58.
PriceRSmithDFranklinG, et al.Oral and topical treatment of painful diabetic polyneuropathy: Practice guideline update summary: Report of the AAN guideline subcommittee. Neurology. 2022;98(1):31-43.
59.
TesfayeSSloanGPetrieJ, et al.Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): A multicentre, double-blind, randomised crossover trial. Lancet. 2022;400(10353):680-690.
60.
AlamUSloanGTesfayeS. Treating pain in diabetic neuropathy: Current and developmental drugs. Drugs. 2020;80(4):363-384.
61.
RosenstockJTuchmanMLaMoreauxLSharmaU. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain. 2004;110(3):628-638.
62.
Pop-BusuiRAngLBoultonAJM, et al.Diagnosis and treatment of painful diabetic peripheral neuropathy. American Diabetes Association; February 2022.
63.
FreemanRRaskinPHewittDJ, et al.Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin. 2007;23(1):147-161.
64.
BuckleyPF. Association between opioid prescribing patterns and opioid overdose-related deaths. Yearb Psychiatry Appl Ment Health. 2012;2012:128-130.
65.
TesfayeSWilhelmSLledoA, et al.Duloxetine and pregabalin: High-dose monotherapy or their combination? The “COMBO-DN study"–a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616-2625.
66.
The effect of intensive diabetes therapy on the development and progression of neuro. Pathy. The diabetes control and complications trial research group. Ann Intern Med. 1995;122(8):561-568.
67.
KennedyWRNavarroXGoetzFCSutherlandDERNajarianJS. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med. 1990;322(15):1031-1037.
68.
AzmiSJeziorskaMFerdousiM, et al.Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. Diabetologia. 2019;62(8):1478-1487.
69.
CallaghanBCChengHTStablesCLSmithALFeldmanEL. Diabetic neuropathy: Clinical manifestations and current treatments. Lancet Neurol. 2012;11(6):521-534.
70.
IshibashiFTaniguchiMKosakaAUetakeHTavakoliM. Improvement in neuropathy outcomes with normalizing HbA1c in patients with type 2 diabetes. Diabetes Care. 2019;42(1):110-118.
71.
SongYZhangHSunJ, et al.Glycemic variability and the risk of diabetic peripheral neuropathy: a meta-analysis. Horm Metab Res. Published online October 11, 2023. doi:https://doi.org/10.1055/a-2165-3579
72.
XuFZhaoLHSuJB,et al.The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab Syndr. 2014 Dec 15;6(1):139.
73.
KurodaNKusunokiYOsugiK, et al.Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo diabetes hypoglycemia cognition complications study. J Diabetes Investig. 2021;12(2):244-253.
74.
LiFZhangYLiH, et al.TIR Generated by continuous glucose monitoring is associated with peripheral nerve function in type 2 diabetes. Diabetes Res Clin Pract. 2020;166:108289.
75.
MayedaLKatzRAhmadI, et al.Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. BMJ Open Diabetes Res Care. 2020;8(1).
76.
GibbonsCHFreemanR. Treatment-induced neuropathy of diabetes: An acute, iatrogenic complication of diabetes. Brain. 2015;138(Pt 1):43-52.
77.
AladdinYJeerakathilTSiddiqiZA. Insulin neuritis and effect of pregabalin. J Clin Neuromuscul Dis. 2017;19(1):1-4.
78.
CaravatiC. Insulin neuritis: A case report. Va Med Mon. 1933;59:745-746.
79.
KludingPMPasnoorMSinghR, et al.The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications. 2012;26(5):424-429.
80.
LookARG. Effects of a long-term lifestyle modification programme on peripheral neuropathy in overweight or obese adults with type 2 diabetes: The Look AHEAD study. Diabetologia. 2017;60(6):980-988.
81.
PerreaultLPanQSchroederEB, et al.Regression from prediabetes to normal glucose regulation and prevalence of microvascular disease in the diabetes prevention program outcomes study (DPPOS). Diabetes Care. 2019;42(9):1809-1815.
82.
OesterleALaufsULiaoJK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120(1):229-243.
83.
DaliriMJohnstonTPSahebkarA. Statins and peripheral neuropathy in diabetic and non-diabetic cases: A systematic review. J Pharm Pharmacol. 2023;75(5):593-611.
84.
KangEYChenTHGargSJ, et al.Association of statin therapy with prevention of vision-threatening diabetic retinopathy. JAMA Ophthalmol. 2019;137(4):363-371.
85.
KristensenFPChristensenDHCallaghanBC, et al.Statin therapy and risk of polyneuropathy in type 2 diabetes: A Danish cohort study. Diabetes Care. 2020;43(12):2945-2952.
86.
SvendsenTKNorregaard HansenPGarcia RodriguezLA, et al.Statins and polyneuropathy revisited: Case-control study in Denmark, 1999-2013. Br J Clin Pharmacol. 2017;83(9):2087-2095.
87.
WarendorfJKVranckenAFJEvan EijkRPAVisserNAvan den BergLHNotermansNC. Statins do not increase risk of polyneuropathy. Neurology. 2019;92(18):e2136-e2144.
ElliottWJ. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: The delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Yearb Cardiol. 2012;2012:99-101.
90.
El-NahasMRElkannishyGAbdelhafezHElkhamisyETEl-SehrawyAA. Oral alpha lipoic acid treatment for symptomatic diabetic peripheral neuropathy: A randomized double-blinded placebo-controlled study. Endocr Metab Immune Disord Drug Targets. 2020;20(9):1531-1534.
91.
PapanasNZieglerD. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15(18):2721-2731.
92.
ZieglerDLowPALitchyWJ, et al.Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: The NATHAN 1 trial. Diabetes Care. 2011;34(9):2054-2060.
93.
AgathosETentolourisAEleftheriadouI, et al.Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy. J Int Med Res. 2018;46(5):1779-1790.
StrackeHGausWAchenbachUFederlinKBretzelRG. Benfotiamine in diabetic polyneuropathy (BENDIP): Results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116(10):600-605.
96.
ApergiKPapanasN. Dietary and nutritional supplementation for painful diabetic neuropathy: A narrative review. Exp Clin Endocrinol Diabetes. 2023;131(12):646-655.
97.
ZieglerDPapanasNSchnellO, et al.Current concepts in the management of diabetic polyneuropathy. J Diabetes Investig. 2021;12(4):464-475.
98.
ZieglerDMovsesyanLMankovskyBGurievaIAbylaiulyZStrokovI. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32(8):1479-1484.
99.
ZieglerDEdmundsonSGurievaIMankovskyBPapanasNStrokovI. Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy. J Diabetes Complications. 2017;31(7):1181-1187.
100.
FonsecaVALaveryLAThethiTK, et al.Metanx in type 2 diabetes with peripheral neuropathy: A randomized trial. Am J Med. 2013;126(2):141-149.
101.
TrippeBSBarrentineLWCuroleMVTipaE. Nutritional management of patients with diabetic peripheral neuropathy with L-methylfolate-methylcobalamin-pyridoxal-5-phosphate: Results of a real-world patient experience trial. Curr Med Res Opin. 2016;32(2):219-227.
102.
DidangelosTKarlaftiEKotzakioulafiE, et al.Vitamin B12 supplementation in diabetic neuropathy: a 1-year, randomized, double-blind, placebo-controlled trial. Nutrients. 2021;13(2).
103.
KarakousisNDPyrgiotiEEGeorgakopoulosPNPapanasN. Vitamin B(12) and diabetic foot: a mini-review. Int J Low Extrem Wounds. Published online November 29, 2022. doi:https://doi.org/10.1177/15347346221143018
104.
LvWSZhaoWJGongSL, et al.Serum 25-hydroxyvitamin D levels and peripheral neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis. J Endocrinol Invest. 2015;38(5):513-518.
105.
KaronovaTStepanovaABystrovaAJudeEB. High-dose vitamin D supplementation improves microcirculation and reduces inflammation in diabetic neuropathy patients. Nutrients. 2020;12(9).
106.
ChenTXingXHuangL, et al.Efficacy and safety of high-dose intramuscular vitamin D(2) injection in type 2 diabetes mellitus with distal symmetric polyneuropathy combined with vitamin D insufficiency: Study protocol for a multicenter, randomized, double-blinded, and placebo-controlled trial. Front Endocrinol (Lausanne). 2023;14:1202917.
107.
HorCPFungWYAngHA, et al.Efficacy of oral mixed tocotrienols in diabetic peripheral neuropathy: A randomized clinical trial. JAMA Neurol. 2018;75(4):444-452.
108.
DavalosLStinoASmithAG. Diagnostic techniques for diabetic peripheral neuropathy. In: TesfayeSGibbonsCHMalikRAVevesA, eds. Diabetic neuropathy: advances in pathophysiology and clinical management. Springer International Publishing; 2023:93-112.
109.
PapanasN. Diabetic neuropathy collection: Progress in diagnosis and screening. Diabetes Ther. 2020;11(4):761-764.
110.
PiaggioDCastaldoRGaribizzoGIadanzaEPecchiaL. A smartphone-based tool for screening diabetic neuropathies: A mHealth and 3D printing approach. Biomed Signal Process Control. 2024;89:105807.
111.
AhlqvistEvan ZuydamNRGroopLCMcCarthyMI. The genetics of diabetic complications. Nat Rev Nephrol. 2015;11(5):277-287.
112.
VeluchamyASmithBHBennettDL. The genomics of diabetic neuropathy. In: TesfayeSGibbonsCHMalikRAVevesA, eds. Diabetic neuropathy: advances in pathophysiology and clinical management. Springer International Publishing; 2023:239-251.
113.
TavakoliMKlingelhöferDFadaviHGronebergDA. The landscape of global research on diabetic neuropathy. Front Endocrinol (Lausanne). 2023;14:1220896.
